The incidence of post-transplant malignancies in kidney transplant recipients treated with Rituximab.

Thomas BacheletJonathan VisentinPhilippine DavisBenjamin TatonGwendaline GuidicelliHannah KaminskiPierre MervilleLionel Couzi

Published in: Clinical transplantation (2020)

Our data do not indicate a higher rate of post-transplantation de novo malignancies after kidney transplantation in high-immunological risk patients who received induction therapy based on ATG and rituximab.

Keyphrases

diffuse large b cell lymphoma
chronic lymphocytic leukemia
hodgkin lymphoma
risk factors
electronic health record
cell therapy
big data
stem cells
mesenchymal stem cells
bone marrow
artificial intelligence
data analysis
deep learning